Henderson Jane 4
4 · Apogee Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Apogee Therapeutics (APGE) CFO Jane Henderson Sells Shares
What Happened Jane Henderson, Chief Financial Officer of Apogee Therapeutics (APGE), sold a total of 2,000 shares in open-market transactions on February 2, 2026, generating approximately $131,629. The sales broke down as: 792 shares at a weighted average of $65.21 ($51,646), 1,108 shares at a weighted average of $66.15 ($73,294), and 100 shares at $66.89 ($6,689). These were dispositions (sales), not purchases.
Key Details
- Transaction date: February 2, 2026 (reported via Form 4 filed Feb 4, 2026).
- Shares sold: 2,000 total (792 @ $65.21; 1,108 @ $66.15; 100 @ $66.89). Total proceeds ≈ $131,629.
- Footnotes: F1—transactions executed pursuant to a Rule 10b5-1 trading plan adopted Sept 2, 2025. F2 & F3—two reported prices are weighted averages; sales occurred across price ranges ($64.80–$65.61 and $65.84–$66.75); breakdowns available on request.
- Shares owned after transaction: not stated in the provided filing excerpt.
- Timeliness: Filing appears timely (Form 4 filed Feb 4 for Feb 2 transactions); no late filing indicated.
Context
- These were open-market sales under a pre-established 10b5-1 plan, which typically reflect prearranged transactions rather than ad hoc insider trades. Sales do not necessarily signal a change in the insider’s view of the company; they may be for diversification, liquidity, or other personal reasons.
Insider Transaction Report
Form 4
Henderson Jane
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-02-02$65.21/sh−792$51,646→ 184,579 total - Sale
Common Stock
[F1][F3]2026-02-02$66.15/sh−1,108$73,294→ 183,471 total - Sale
Common Stock
[F1]2026-02-02$66.89/sh−100$6,689→ 183,371 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.84 to $66.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson|2026-02-04